CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD).

[1]  Xinrui Wang,et al.  Genotype-Guided Antiplatelet Therapy Versus Standard Therapy for Patients with Coronary Artery Disease: An Updated Systematic Review and Meta-Analysis. , 2022, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[2]  R. V. van Schaik,et al.  Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs , 2021, European Journal of Human Genetics.

[3]  Hao Li,et al.  Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA. , 2021, The New England journal of medicine.

[4]  I. Porto,et al.  Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis , 2021, The Lancet.

[5]  K. Bailey,et al.  Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy: A Meta-Analysis. , 2021, JACC. Cardiovascular interventions.

[6]  K. Bailey,et al.  Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. , 2020, JAMA.

[7]  Manesh R. Patel,et al.  CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial. , 2020, American heart journal.

[8]  M. Postma,et al.  A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI. , 2019, The New England journal of medicine.

[9]  Juey-Jen Hwang,et al.  CYP2C19 Polymorphism is Associated With Amputation Rates in Patients Taking Clopidogrel After Endovascular Intervention for Critical Limb Ischaemia. , 2019, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[10]  Deepak L. Bhatt,et al.  Personalized antiplatelet therapy in patients with coronary artery disease undergoing percutaneous coronary intervention: A network meta‐analysis of randomized clinical trials , 2019, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[11]  Z. Hao,et al.  Genotype-guided antiplatelet therapy compared with conventional therapy for patients with acute coronary syndromes: a systematic review and meta-analysis , 2019, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[12]  John V. White,et al.  Global vascular guidelines on the management of chronic limb-threatening ischemia. , 2019, Journal of vascular surgery.

[13]  Yujie Zhou,et al.  CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: A systematic review and meta-analysis , 2019, Platelets.

[14]  Deepak L. Bhatt,et al.  CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta‐analysis of randomized clinical trials , 2018, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[15]  G. Santulli,et al.  Update on peripheral artery disease: Epidemiology and evidence-based facts. , 2018, Atherosclerosis.

[16]  J. Bosch,et al.  Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. , 2018, Lancet.

[17]  D. Thijssen,et al.  Carotid Artery Reactivity Predicts Events in Peripheral Arterial Disease Patients , 2017, Annals of surgery.

[18]  K. Mahaffey,et al.  Ticagrelor Versus Clopidogrel in Symptomatic Peripheral Artery Disease , 2017, The New England journal of medicine.

[19]  S. Johnston,et al.  Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis , 2017, Circulation.

[20]  K. Woo,et al.  The Diagnostic Utility of the Point-of-Care CYP2C19 Genotyping Assay in Patients with Acute Coronary Syndrome Dosing Clopidogrel: Comparison with Platelet Function Test and SNP Genotyping. , 2016, Annals of clinical and laboratory science.

[21]  Bo Wang,et al.  Clinical Value of CYP2C19 Genetic Testing for Guiding the Antiplatelet Therapy in a Chinese Population , 2016, Journal of cardiovascular pharmacology.

[22]  Li Peng,et al.  Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis. , 2015, Thrombosis research.

[23]  M. Wiese,et al.  CYP2C19 Genotype Has a Greater Effect on Adverse Cardiovascular Outcomes Following Percutaneous Coronary Intervention and in Asian Populations Treated With Clopidogrel: A Meta-Analysis , 2014, Circulation. Cardiovascular genetics.

[24]  W. Guo,et al.  Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease. , 2014, Journal of vascular surgery.

[25]  I. Zineh,et al.  Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers , 2014, Journal of clinical pharmacology.

[26]  Xiang Ma,et al.  Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial. , 2013, International journal of cardiology.

[27]  Deepak L. Bhatt,et al.  The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. , 2012, European heart journal.

[28]  P. Gurbel,et al.  Effect of CYP2C19*2 and *3 Loss-of-Function Alleles on Platelet Reactivity and Adverse Clinical Events in East Asian Acute Myocardial Infarction Survivors Treated With Clopidogrel and Aspirin , 2011, Circulation. Cardiovascular interventions.

[29]  Deepak L. Bhatt,et al.  Genetic Polymorphisms and the Impact of a Higher Clopidogrel Dose Regimen on Active Metabolite Exposure and Antiplatelet Response in Healthy Subjects , 2011, Clinical pharmacology and therapeutics.

[30]  M. Farmen,et al.  Genetic Variation in Metabolizing Enzyme and Transporter Genes: Comprehensive Assessment in 3 Major East Asian Subpopulations With Comparison to Caucasians and Africans , 2010, Journal of clinical pharmacology.

[31]  D Bergqvist,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients , 2010, Journal of thrombosis and haemostasis : JTH.

[32]  J. Ferrières,et al.  Genetic determinants of response to clopidogrel and cardiovascular events. , 2009, The New England journal of medicine.

[33]  B. Giusti,et al.  Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. , 2009, The American journal of cardiology.

[34]  G. Montalescot,et al.  Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study , 2009, The Lancet.

[35]  G. Montalescot,et al.  Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. , 2008, JACC. Cardiovascular interventions.

[36]  A. Kastrati,et al.  Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. , 2008, European heart journal.

[37]  M. Fromm,et al.  Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. , 2008, Journal of the American College of Cardiology.

[38]  E. Antman,et al.  Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). , 2006, American heart journal.

[39]  R. Collins,et al.  Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial , 2005, The Lancet.

[40]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[41]  R. Rutherford,et al.  Recommended standards for reports dealing with lower extremity ischemia: revised version. , 1997, Journal of vascular surgery.

[42]  David Schultz,et al.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996, The Lancet.

[43]  Jeroen J. Bax,et al.  Editor's Choice - 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). , 2018, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[44]  Xuan Niu 牛 璇,et al.  CYP2C19 polymorphism and clinical outcomes among patients of different races treated with clopidogrel: A systematic review and meta-analysis , 2015, Journal of Huazhong University of Science and Technology [Medical Sciences].

[45]  B. Kanna,et al.  A double blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. , 2008, European heart journal.

[46]  D. Flockhart,et al.  Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism , 2002, Clinical pharmacokinetics.